Aculeus Therapeutics is a Biotech company based in Melbourne Australia, developing small molecule drugs that modulate the immune system for the treatment of cancer and other serious diseases. Aculeus is doing this by developing drugs that target the Stimulator of Interferon Genes (STING) biochemical pathway.
Aculeus in-licensed its lead programs, STING and ENPP1, in 2020 from the CRC for Cancer Therapeutics, a Public Private Partnership between a number of Australia’s leading Medical Research Institutes, Universities and Industry partners with a track record of scientific and commercial success.
Company Details
- Employees
- 8
- Founded
- -
- Address
- 30 Flemington Rd, Parkville,vic 3052,australia
- Industry
- Biotechnology
- HQ
- Parkville, VIC
Aculeus Therapeutics Questions
Aculeus Therapeutics's LinkedIn profile is https://au.linkedin.com/company/aculeus-therapeutics
Aculeus Therapeutics has
8 employees.
View email and phone details for 8
employees at Aculeus Therapeutics.
Aculeus Therapeutics's industry is
Biotechnology
Aculeus Therapeutics's top competitors are
Agilex Biolabs Pty Ltd,
Biocina,
Oncology One Pty Ltd,
Amplia Therapeutics Limited,
Ipsen,
Synthesis Research,
Anaxis Pharma,
Canthera Discovery (Canthera Discovery Ltd),
Cell Therapies Pty Ltd,
Imugene Limited.
Aculeus Therapeutics's categories are Biotechnology
Aculeus Therapeutics's founding year is 2020
